PFIZER.NS Profit & Loss
Pfizer Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:42
| Line item | FY2022-23 standalone basis | FY2023-24 standalone basis | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹2,424.76 Cr. | ₹2,193.17 Cr. | ₹2,281.35 Cr. | ₹2,519.65 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹101.05 Cr. | ₹180.51 Cr. | ₹172.25 Cr. | ₹187.95 Cr. | OtherIncome |
| Total Income | ₹2,525.81 Cr. | ₹2,373.68 Cr. | ₹2,453.60 Cr. | ₹2,707.60 Cr. | Income |
| Cost of Materials Consumed | ₹345.27 Cr. | ₹335.80 Cr. | ₹272.34 Cr. | ₹309.51 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹471.92 Cr. | ₹468.59 Cr. | ₹512.75 Cr. | ₹608.39 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹56.48 Cr. | ₹-11.82 Cr. | ₹25.36 Cr. | ₹-33.59 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹331.68 Cr. | ₹347.80 Cr. | ₹371.33 Cr. | ₹367.97 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹13.39 Cr. | ₹15.41 Cr. | ₹8.41 Cr. | ₹9.48 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹105.51 Cr. | ₹62.28 Cr. | ₹60.79 Cr. | ₹57.73 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹410.55 Cr. | ₹417.50 Cr. | ₹359.34 Cr. | ₹363.28 Cr. | OtherExpenses |
| Total Expenses | ₹1,734.80 Cr. | ₹1,635.56 Cr. | ₹1,610.32 Cr. | ₹1,682.77 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹791.01 Cr. | ₹738.12 Cr. | ₹843.28 Cr. | ₹1,024.83 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹33.00 Cr. | ₹7.95 Cr. | ₹172.81 Cr. | ₹-49.16 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹824.01 Cr. | ₹746.07 Cr. | ₹1,016.09 Cr. | ₹975.67 Cr. | ProfitBeforeTax |
| Tax Expense | ₹200.08 Cr. | ₹194.74 Cr. | ₹248.49 Cr. | ₹253.24 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹623.93 Cr. | ₹551.33 Cr. | ₹767.60 Cr. | ₹722.43 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | N/A | N/A | N/A | N/A | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹136.38 | ₹120.51 | ₹167.79 | ₹157.92 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹136.38 | ₹120.51 | ₹167.79 | ₹157.92 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from PFIZER.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).